Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring

• Published in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2023-11, Vol.1230, p.123905-123905, Article 123905
• Main Authors: West, Raymond E., Oberly, Patrick J., Riddler, Sharon A., Nolin, Thomas D., Devanathan, Aaron S.
• Format: Article
• Language: English
• Subjects: Anti-HIV Agents - therapeutic use; Anti-Retroviral Agents; Antiretroviral; Chromatography, High Pressure Liquid; HIV; HIV Infections - drug therapy; Humans; Lenacapavir; Tandem Mass Spectrometry; Therapeutic drug monitoring; UHPLC-MS/MS; United States
• ISSN: 1570-0232; 1873-376X; 1873-376X
• DOI: 10.1016/j.jchromb.2023.123905

•Lenacapavir is a first-in-class capsid inhibitor.•Lenacapavir was approved for the treatment of HIV in treatment-experienced patients.•Quantifying concentrations in plasma ensures adequate antiretroviral exposure.•A UHPLC-MS/MS method was validated to quantify lenacapavir in human plasma.•The method was successfully applied to a clinical sample. Although current antiretroviral therapy (ART) effectively suppresses HIV in the blood, regimens may fail due to suboptimal treatment history and non-adherence to ART. In these scenarios, accumulation of viral resistance mutations to ART drug classes may occur. For these treatment-experienced people living with HIV (PLWH), activity against resistant viral strains is required; lack of therapeutic efficacy will result in continued viral replication and progression to acquired immunodeficiency syndrome. New treatment options have emerged. Lenacapavir is a first-in-class long-acting HIV-1 capsid inhibitor approved for the treatment of HIV in treatment-experienced patients. Lenacapavir is approved with an initiation regimen of oral and subcutaneous injection dosing followed by subcutaneous self-injection every 6 months. With infrequent dosing, therapeutic drug monitoring may be necessary to ensure adequate concentrations are consistently achieved in the plasma to assure treatment adherence and prevent further HIV resistance formation. To this end, we developed and validated a highly selective ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method to quantify lenacapavir concentrations in human plasma. A simple protein precipitation with acetonitrile followed by supernatant dilution was performed. Lenacapavir and its stable labeled internal standard were separated at 1.90 min using a multi-step UPLC gradient. The assay for lenacapavir quantification was extensively validated according to the United States Food and Drug Administration Bioanalytical Guidelines over a clinically relevant range of 0.1 to 500 ng/mL with excellent linearity (R2 ≥ 0.9960). This analytical method achieves acceptable performance of trueness (89.7–104.1 %), repeatability, and precision (CV